Health News
FDA Drug Safety Communication: Mirapex and Heart Failure
The US Food and Drug Administration (FDA) is informing the public about a possible increased risk of heart failure with Mirapex (pramipexole), a drug used to treat Parkinson’s disease and restless legs syndrome.
Cold, Hot, But Don't Burn!
One of the first things people turn to for muscle aches and sore joints are creams and gels that cause that hot-cold tingly sensation.
Breakdown of Triathlon Injuries
Five weeks after a bicycle crash that led to back and collarbone surgery, triathlete Lukas Verzbicas is out of the hospital. The injuries occurred during a training ride, but what happens when they occur during a real race?
H1N1 Vaccine Linked to Nervous Disorder
One of the conditions known to be a risk following some flu vaccinations is the autoimmune disease Guillain-Barre syndrome.
Omega-3 Oils Keep the Swelling Down
Inflammation occurs with many chronic and acute diseases. Fish oil, a source of omega-3 fatty acids, may help curb this painful symptom.
FDA Issues Warning on Natural Supplement
There are countless dietary supplements marketed as natural remedies for pain relief. In some instances, these supplements turn out to be neither natural nor safe, which seems to be the case for Reumofan Plus.
FDA Issues Alert on Reumofan Plus
The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a “natural” dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.
Hospira Alert: Carpuject May Contain More Than the Intended Fill Volume
FDA is alerting healthcare providers of a potential safety risk in some Carpuject pre-filled cartridges manufactured by Hospira , Inc.
Multiple Diseases, Multiple Problems
In the age of multitasking, “one thing at a time” is as outdated as a polyester leisure suit. The same is true for doctors treating just one disease as it can lead to confusion and inferior care.
Cardiovascular Monitoring With Gilenya
The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya ( fingolimod ).